- Home
- NMG vs CADL Comparison
NMG vs CADL Comparison
Compare NMG & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NMG | CADL |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.7M | 280.3M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NMG | CADL |
|---|---|---|
| Price | $2.30 | $5.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $4.16 | ★ $19.14 |
| AVG Volume (30 Days) | 748.6K | ★ 1.3M |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $4.25 |
| 52 Week High | $6.06 | $9.01 |
Technical Indicators
Market Signals| Indicator | NMG | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 47.73 |
| Support Level | $2.07 | $4.57 |
| Resistance Level | $2.43 | $5.42 |
| Average True Range (ATR) | 0.13 | 0.24 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 68.92 | 54.89 |
Price Performance
Historical ComparisonAbout NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.